Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Indegene is strengthening its Consulting Practice to help life sciences organizations address their most pressing challenges with speed, impact, and accountability
Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program
Pantoprazole sodium is a proton pump inhibitor reduces stomach acid
These findings follow positive Phase 3 results presented earlier this year
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
Subscribe To Our Newsletter & Stay Updated
